Mavrikaki Maria, Pravetoni Marco, Page Sarah, Potter David, Chartoff Elena
Department of Psychiatry, Harvard Medical School, McLean Hospital, 115 Mill Street, Belmont, MA, 02478, USA.
Department of Medicine and Pharmacology, Minneapolis Medical Research Foundation, University of Minnesota, Minneapolis, MN, 55455, USA.
Psychopharmacology (Berl). 2017 Mar;234(6):977-987. doi: 10.1007/s00213-017-4536-6. Epub 2017 Jan 27.
Oxycodone is one of the most widely prescribed painkillers in the USA. However, its use is complicated by high abuse potential. As sex differences have been described in drug addiction, the present study tested for sex differences in intravenous oxycodone self-administration in rats.
Male and female Sprague-Dawley rats were implanted with jugular vein catheters and trained to self-administer oxycodone (0.03 mg/kg/infusion) under fixed ratio 1 (FR1), FR2, and FR5 schedules of reinforcement followed by a dose-response study to assess sensitivity to the reinforcing effects of oxycodone. In separate rats, sucrose pellet self-administration was assessed under an FR1 schedule to determine whether sex differences in oxycodone self-administration could be generalized across reinforcers. In separate rats, oxycodone distribution to plasma and brain was measured after intravenous drug delivery.
In the first 3 trials under an FR1 schedule of reinforcement, male rats self-administered more oxycodone than females. In contrast, females self-administered more sucrose pellets. Under FR2 and FR5 schedules, no significant sex differences in oxycodone intake were observed, although female rats had significantly more inactive lever presses. Male and female rats showed similar inverted U-shaped dose-effect functions, with females tending to self-administer more oxycodone than males at higher doses. No significant sex differences were observed in plasma or brain oxycodone levels, suggesting that sex differences in oxycodone self-administration behavior were not due to pharmacokinetics.
Our results suggest subtle sex differences in oxycodone self-administration, which may influence the abuse liability of oxycodone and have ramifications for prescription opioid addiction treatment.
羟考酮是美国处方最广泛的止痛药之一。然而,其高滥用潜力使使用情况变得复杂。由于药物成瘾存在性别差异,本研究测试了大鼠静脉注射羟考酮自我给药中的性别差异。
给雄性和雌性斯普拉格-道利大鼠植入颈静脉导管,并训练它们在固定比率1(FR1)、FR2和FR5强化程序下自我给药羟考酮(0.03毫克/千克/输注),随后进行剂量反应研究以评估对羟考酮强化作用的敏感性。在另一组大鼠中,在FR1程序下评估蔗糖颗粒自我给药,以确定羟考酮自我给药中的性别差异是否可推广到其他强化物。在另一组大鼠中,静脉给药后测量羟考酮在血浆和大脑中的分布。
在FR1强化程序的前3次试验中,雄性大鼠自我给药的羟考酮比雌性大鼠多。相比之下,雌性大鼠自我给药更多蔗糖颗粒。在FR2和FR5程序下,未观察到羟考酮摄入量的显著性别差异,尽管雌性大鼠无活动压杆次数明显更多。雄性和雌性大鼠表现出相似的倒U形剂量效应函数,在较高剂量下雌性大鼠倾向于比雄性大鼠自我给药更多羟考酮。血浆或大脑中羟考酮水平未观察到显著性别差异,表明羟考酮自我给药行为的性别差异不是由药代动力学引起的。
我们的结果表明羟考酮自我给药存在细微的性别差异,这可能影响羟考酮的滥用倾向,并对处方阿片类药物成瘾治疗产生影响。